<DOC>
	<DOCNO>NCT00459836</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , PR-104 , docetaxel , gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . PURPOSE : This phase I trial study side effect best dose PR-104 give together docetaxel gemcitabine treat patient solid tumor .</brief_summary>
	<brief_title>PR-104 Docetaxel Gemcitabine Treating Patients With Solid Tumors</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose PR-104 combination docetaxel gemcitabine hydrochloride patient solid tumor . Secondary - Determine safety PR-104 combination docetaxel gemcitabine hydrochloride patient . - Determine antitumor activity regimens use disease-specific parameter , exam , scan , tumor marker , patient . - Determine pharmacokinetics PR-104 alcohol metabolite patient . - Determine pharmacokinetics docetaxel gemcitabine hydrochloride administer PR-104 . - Collect plasma sample assessment potential biomarkers tumor hypoxia patient . - Examine metabolic change tumor use fludeoxyglucose F 18 positron emission tomography ( PET ) PET image fluoromisonidazole F 18 ( hypoxia-targeted radiopharmaceutical ) patient . OUTLINE : This nonrandomized , open-label , uncontrolled , multicenter , dose-escalation study PR-104 . Patients assign 1 2 treatment group accord patient 's malignancy prior treatment history . - Group 1 : Patients receive docetaxel IV 60 minute PR-104 IV 60 minute day 1 . - Group 2 : Patients receive gemcitabine hydrochloride IV 30 minute PR-104 IV 60 minute day 1 8 . In group , treatment repeat every 21 day 8 course absence unacceptable toxicity disease progression . Cohorts 3-6 patient group receive escalate dos PR-104 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Blood collect baseline periodically course 1 pharmacokinetic analysis . Plasma sample analyze biomarkers tumor hypoxia baseline day 2 8 . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm solid tumor malignancy Treatment either docetaxel gemcitabine hydrochloride combination investigational agent reasonable Measurable evaluable disease PATIENT CHARACTERISTICS : ECOG performance status 01 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 9.0 g/dL ( red blood cell transfusion allow ) Bilirubin normal ALT AST ≤ 2.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN PT/INR aPTT ≤ 1.1 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day completion study therapy No evidence significant medical disorder , include uncontrolled infection infection require concurrent parenteral antibiotic , laboratory finding , opinion investigator , would preclude study compliance No known HIV positivity No hepatitis B surface antigen positivity No hepatitis C positivity abnormal liver function test PRIOR CONCURRENT THERAPY : No prior radiotherapy &gt; 25 % bone marrow No prior highdose chemotherapy ( include condition either myeloablative nonmyeloablative transplantation ) No 3 prior chemotherapy regimens More 4 week since prior major surgery More 4 week since prior investigational traditional anticancer therapy ( include radiotherapy ) ( 6 week nitrosoureas mitomycin C ) The following medications/treatments permit trial : Any licensed investigational anticancer treatment Prophylactic hematopoietic growth factor Irradiation therapy ( palliative therapeutic ) unless give absence tumor progression Concurrent systemic steroid allow provided patient stable dose ≥ 2 week prior study treatment Concurrent androgendeprivation therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>